東誠藥業(002675.SZ)子公司與Exalenz簽署獨家經銷協議
格隆匯8月14日丨東誠藥業(002675.SZ)公佈,2019年8月13日,公司全資子公司煙台東誠大洋製藥有限公司(“大洋製藥”)與Exalenz Bioscience Ltd.(“Exalenz”)簽署了獨家經銷協議,大洋製藥在中國大陸獨家經銷尿素[13C]呼氣試驗產品。
按照該協議,大洋製藥將作為尿素[13C]呼氣試驗產品及服務的獨家經銷商,負責在中國大陸推廣和銷售。合作期限:自生效日期起該協議對雙方生效,初始期限為5年。如果依照協議未提前中止,協議的條款應在初始期限結束時自動續期,為期2年。
該協議簽訂後,公司子公司大洋製藥將擁有Exalenz尿素[13C]呼氣試驗產品及服務的獨家代理銷售權,該產品作為幽門螺桿菌感染的非侵入式診斷醫療檢測的主流手段,將有助於公司補強診斷類藥物產品管線,拓寬收入和利潤來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.